Rare diseases
Investigational molecules
Locations
Study of Zasocitinib and Apremilast for Adults with Active Psoriatic Arthritis Who Have Not Used Biologic Medicines
BelgiumA study to evaluate the long-term safety of apremilast in children with oral ulcers from Behçet’s disease or juvenile psoriatic arthritis
GreeceStudy of apremilast compared to placebo in children aged 5-17 years with juvenile psoriatic arthritis
AustriaStudy on the Effectiveness and Safety of Apremilast for Patients Aged 6 and Older with Generalized Epidermolysis Bullosa Simplex
FranceStudy on Apremilast for Treating Oral Ulcers in Children with Behçet's Disease
FranceStudy on Reducing Immunosuppressive Drugs in Adults with Psoriatic Arthritis: Methotrexate Disodium, Abatacept, and Certolizumab Pegol
GermanyStudy of apremilast‑induced headache and migraine in women with migraine without aura
DenmarkStudy on Apremilast for Patients with Severe Recurrent Mouth Ulcers Resistant to Colchicine
FranceStudy of zasocitinib (TAK-279) and apremilast compared to placebo in adults with moderate to severe plaque psoriasis
BulgariaStudy of TAK-279 and apremilast for adults with moderate to severe plaque psoriasis
GermanyStudy on the Effectiveness and Safety of ESK-001 and Apremilast for Patients with Moderate to Severe Plaque Psoriasis
AustriaStudy on the Effectiveness and Safety of ESK-001 and Apremilast for Adults with Moderate to Severe Plaque Psoriasis
BelgiumTell us about your condition – we search every trial in Europe and connect you with the right site.
